Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Artif Organs ; 46(12): 629-635, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37926985

RESUMEN

INTRODUCTION: Severe COVID-19 is associated with a dysregulated immune response that usually leads to cytokine release syndrome. This study aimed to compare the use of extracorporeal blood purification therapy (Oxiris®) versus standard continuous renal replacement therapy (CRRT) in critically-ill patients with severe COVID-19. METHODS: This was a national, multicenter, retrospective study of patients with COVID-19 admitted to the intensive care unit (ICU) between March and October 2020 who required CRRT. Patients were categorized into two groups: Oxiris® CRRT and standard CRRT. The primary outcome was the number of patients alive and ventilator-free at 30-days post-CRRT treatment. Key secondary endpoints included change in inflammatory markers, Sequential Organ Failure Assessment (SOFA) scores, and PaO2/FiO2 ratio at 24- and 72-h post Oxiris® initiation. RESULTS: Thirty-five patients received Oxiris® CRRT and 23 patients received standard CRRT. The primary outcome was 31.4% in the Oxiris® group versus 4.3% in the standard CRRT group (adjusted odds ratio 5.97, 95% confidence interval [CI], 0.64-55.6; p = 0.117). In the Oxiris® group, interleukin-6 (IL-6) concentrations significantly decreased at 24 and 72-h (p = 0.033) and PaO2/FiO2 ratio significantly increased at 24 and 72 h after Oxiris® initiation (p = 0.001). There was no significant change in SOFA scores at 24- and 72-h after Oxiris® initiation. CONCLUSION: The number of patients alive and ventilator-free at 30-days was higher in the Oxiris® group than that in the standard CRRT group; however, the difference did not reach statistical significance after adjusting for the baseline severity of illness. There was a significant reduction in IL-6 and significant improvement in PaO2/FiO2 ratio after Oxiris® CRRT initiation.


Asunto(s)
Lesión Renal Aguda , COVID-19 , Terapia de Reemplazo Renal Continuo , Humanos , Terapia de Reemplazo Renal Continuo/efectos adversos , Enfermedad Crítica , COVID-19/terapia , Estudios Retrospectivos , Interleucina-6 , Terapia de Reemplazo Renal , Lesión Renal Aguda/terapia
2.
Heliyon ; 9(5): e15895, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37215844

RESUMEN

With global urbanization on the increase and cities now hosting more than half of the planet's population, there are concerns regarding the protection of urban commons as part of sustainability efforts, especially in sub-Saharan Africa. Decentralized urban planning is a policy tool and practice that is used to organize urban infrastructure for sustainable development. Yet, how it can be used to sustain the urban commons remains fragmented in the literature. This study reviews and synthesizes urban planning and urban commons literature using the Institutional Analysis and Development Framework and the non-cooperative game theory to identify how urban planning can protect and sustain the urban commons - green commons, land commons, and water commons - in Ghana. The study, based on the determination of different theoretical scenarios for the urban commons, identified that decentralized urban planning can help sustain the urban commons, but it is operationalized in an unfavorable political environment. For green commons, there are competing interests and poor coordination amongst planning institutions, and the absence of self-organizing bodies in managing the use of such resources. For land commons, increased land litigations are characterized by corruption and poor management of land cases in the formal land courts, and despite the existence of self-organizing institutions, these institutions have failed to act responsibly to protect land commons due to the increasing demands and values (profitability) of lands in urban areas. For water commons, urban planning has not been fully decentralized and there is also the absence of self-organizing bodies in urban water use and management. This is coupled with the waning of customary water protection provisions in urban centers. Based on the findings, the study generally proposes institutional strengthening as the bedrock for enhancing the sustainability of the urban commons through urban planning and should therefore be of policy focus moving forward.

3.
Shock ; 59(5): 697-701, 2023 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-36870070

RESUMEN

ABSTRACT: Purpose: The aim of the study is to evaluate the effect of combined hydrocortisone, vitamin C, and thiamine (triple therapy) on the mortality of patients with septic shock. Methods : This multicenter, open-label, two-arm parallel-group, randomized controlled trial was conducted in four intensive care units in Qatar. Adult patients diagnosed with septic shock requiring norepinephrine at a rate of ≥0.1 µg/kg/min for ≥6 h were randomized to a triple therapy group or a control group. The primary outcome was in-hospital mortality at 60 days or at discharge, whichever occurred first. Secondary outcomes included time to death, change in Sequential Organ Failure Assessment (SOFA) score at 72 h of randomization, intensive care unit length of stay, hospital length of stay, and vasopressor duration. Results: A total of 106 patients (53 in each group) were enrolled in this study. The study was terminated early because of a lack of funding. The median baseline SOFA score was 10 (interquartile range, 8-12). The primary outcomes were similar between the two groups (triple therapy, 28.3% vs. control, 35.8%; P = 0.41). Vasopressor duration among the survivors was similar between the two groups (triple therapy, 50 h vs. control, 58 h; P = 0.44). Other secondary and safety endpoints were similar between the two groups. Conclusion: Triple therapy did not improve in-hospital mortality at 60 days in critically ill patients with septic shock or reduce the vasopressor duration or SOFA score at 72 h. Trial Registration:ClinicalTrials.gov identifier: NCT03380507. Registered on December 21, 2017.


Asunto(s)
Choque Séptico , Tiamina , Adulto , Humanos , Tiamina/uso terapéutico , Ácido Ascórbico/uso terapéutico , Hidrocortisona/uso terapéutico , Vitaminas , Vasoconstrictores/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...